{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T07:05:36Z","timestamp":1788505536054,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"vor","delay-in-days":3481,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1111\/jth.12224","type":"journal-article","created":{"date-parts":[[2013,4,11]],"date-time":"2013-04-11T04:53:02Z","timestamp":1365655982000},"page":"1059-1068","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Drospirenone and non-fatal venous thromboembolism: is there a risk difference by dosage of ethinyl-estradiol?"],"prefix":"10.1016","volume":"11","author":[{"given":"S.T.","family":"Bird","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.C.","family":"Delaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Etminan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Brophy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.G.","family":"Hartzema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.12224_bb0010","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.contraception.2006.12.019","article-title":"The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation","volume":"75","author":"Dinger","year":"2007","journal-title":"Contraception"},{"key":"10.1111\/jth.12224_bb0015","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/01.AOG.0000279448.62221.a8","article-title":"Risk of thromboembolism in women taking ethinyestradiol\/drospirenone and other oral contraceptives","volume":"110","author":"Seeger","year":"2007","journal-title":"Obstet Gynecol"},{"key":"10.1111\/jth.12224_bb0020","article-title":"The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA study","volume":"339","author":"van Hylckama","year":"2009","journal-title":"BMJ"},{"key":"10.1111\/jth.12224_bb0025","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2890","article-title":"Hormonal contraception and risk of venous thromboembolism: national follow-up study","volume":"339","author":"Lidegaard","year":"2009","journal-title":"BMJ"},{"key":"10.1111\/jth.12224_bb0030","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d2139","article-title":"Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database","volume":"342","author":"Parkin","year":"2011","journal-title":"BMJ"},{"key":"10.1111\/jth.12224_bb0035","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d2151","article-title":"Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using united States claims data","volume":"342","author":"Jick","year":"2011","journal-title":"BMJ"},{"key":"10.1111\/jth.12224_bb0040","doi-asserted-by":"crossref","first-page":"E1319","DOI":"10.1503\/cmaj.110463","article-title":"Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study [published online ahead of print November 7, 2011]","volume":"183","author":"Gronich","year":"2011","journal-title":"CMAJ"},{"key":"10.1111\/jth.12224_bb0045","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d6423","article-title":"Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: danish cohort study, 2001-9","volume":"343","author":"Lidegaard","year":"2011","journal-title":"BMJ"},{"key":"10.1111\/jth.12224_bb0050","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.contraception.2012.09.015","article-title":"Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users","volume":"87","author":"Sidney","year":"2013","journal-title":"Contraception"},{"key":"10.1111\/jth.12224_bb0055","unstructured":"Yaz. Wayne, NJ: Bayer Healthcare Pharmaceuticals, Inc.; 2010."},{"key":"10.1111\/jth.12224_bb0060","unstructured":"University of Arkansas for Medical Sciences. LifeLink health plan claims database: overview and study design issues [homepage on the internet]. c2010 [updated 2010; cited 2013 April 2]. Available from http:\/\/www.uams.edu\/TRI\/hsrcore\/Lifelink_Health_Plan_Claims_Data_Design Issues_wcost_April2010[1].pdf. Accessed 23 April 2013."},{"key":"10.1111\/jth.12224_bb0065","first-page":"4","article-title":"Problems in dealing with missing data and informative censoring in clinical trials","volume":"3","author":"Shih","year":"2002","journal-title":"Curr Control Trials Cardiovasc Med"},{"key":"10.1111\/jth.12224_bb0070","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1001\/archinte.164.18.1965","article-title":"Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review","volume":"164","author":"Gomes","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1111\/jth.12224_bb0075","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.contraception.2005.09.015","article-title":"A prospective study on the hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol","volume":"73","author":"Kluft","year":"2006","journal-title":"Contraception"},{"key":"10.1111\/jth.12224_bb0080","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0010-7824(96)00112-6","article-title":"The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. The transnational research group on oral contraceptives and the health of young women","volume":"54","author":"Lewis","year":"1996","journal-title":"Contraception"},{"key":"10.1111\/jth.12224_bb0085","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0010-7824(97)00119-4","article-title":"First-time use of newer oral contracepties and the risk of venous thromboembolism","volume":"56","author":"Suissa","year":"1997","journal-title":"Contraception"},{"key":"10.1111\/jth.12224_bb0090","series-title":"Pharmacoepidemiology and Therapeutic Risk Management","first-page":"751","article-title":"Advanced pharmacoepidemiologic reasoning: the story of second- and third- generation oral contraceptives: the story of the transnational study on oral contraceptives and the health of young women","author":"Lewis","year":"2008"},{"key":"10.1111\/jth.12224_bb0095","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.contraception.2010.02.009","article-title":"Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome","volume":"82","author":"Kriplani","year":"2010","journal-title":"Contraception"},{"key":"10.1111\/jth.12224_bb0100","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/13625180600983082","article-title":"Efficacy of an oral contraceptive containing drospirenone in the treatment of women with polycystic ovary syndrome","volume":"12","author":"Pehlivanov","year":"2007","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1111\/jth.12224_bb0105","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.fertnstert.2005.07.1311","article-title":"Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism","volume":"85","author":"Batukan","year":"2006","journal-title":"Fertil Steril"},{"key":"10.1111\/jth.12224_bb0110","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/pds.1554","article-title":"Supplementary data collection with case-cohort analysis to address potential confounding in a cohort study of thromboembolism in oral contraceptive initiators matched on claims-based propensity scores","volume":"17","author":"Eng","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1111\/jth.12224_bb0115","first-page":"S74","article-title":"Oral contraceptives and the risk of VTE: reanalysis of the EURAS\/LASS Study [abstract]","volume":"20","author":"Dinger","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1111\/jth.12224_bb0120","unstructured":"Food and Drug Administration. Drospirenone-containing combination oral contraceptives briefing document [homepage on the internet]. C2011. [updated 2011 Dec 7; cited 2013 April 2]. Available from http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/ReproductiveHealthDrugsAdvisoryCommittee\/UCM282464.pdf. Accessed 23 April 2013."},{"key":"10.1111\/jth.12224_bb0125","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1749-6632.1995.tb31386.x","article-title":"Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity","volume":"761","author":"Muhn","year":"1995","journal-title":"Ann N Y Acad Sci"},{"key":"10.1111\/jth.12224_bb0130","first-page":"1816","article-title":"Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism","volume":"80","author":"Oelkers","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 3","key":"10.1111\/jth.12224_bb0135","first-page":"19","article-title":"Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone","volume":"7","author":"Oelkers","year":"2002","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1111\/jth.12224_bb0140","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3109\/09513590009167683","article-title":"Effect of an oral contraceptive containing drospirenone on the renin-angiotension-aldosterone system in healthy female volunteers","volume":"14","author":"Oelkers","year":"2000","journal-title":"Gynecol Endocrinol"},{"key":"10.1111\/jth.12224_bb0145","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00404-008-0907-x","article-title":"Effects of two combined oral contraceptives containing ethinyl estradiol 30 microg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure","volume":"280","author":"Yildizhan","year":"2009","journal-title":"Arch Gynecol Obstet"},{"key":"10.1111\/jth.12224_bb0150","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2147\/TCRM.S6864","article-title":"Use of ethinylestradiol\/drospirenone combination in patients with the polycystic ovary syndrome","volume":"4","author":"Mathur","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"10.1111\/jth.12224_bb0155","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/humrep\/der396","article-title":"Consensus on women's health aspects of polycystic ovary syndrome (PCOS)","volume":"27","year":"2012","journal-title":"Hum Reprod"},{"key":"10.1111\/jth.12224_bb0160","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3109\/09513590.2012.743007","article-title":"Polycystic ovary syndrome and combined oral contraceptive use: a comparison of clinical practice in the United States to treatment guidelines","volume":"29","author":"Bird","year":"2013","journal-title":"Gynecol Endocrinol"},{"key":"10.1111\/jth.12224_bb0165","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1472-6904-11-23","article-title":"The association between drospirenone and hyperkalemia: a comparative-safety study","volume":"11","author":"Bird","year":"2011","journal-title":"BMC Clin Pharmacol"},{"key":"10.1111\/jth.12224_bb0170","doi-asserted-by":"crossref","first-page":"E115","DOI":"10.1503\/cmaj.120677","article-title":"Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis","volume":"185","author":"Bird","year":"2013","journal-title":"CMAJ"},{"key":"10.1111\/jth.12224_bb0175","first-page":"377","article-title":"Is polycystic ovary syndrome another risk factor for venous thromboembolism? United States, 2003\u20132008","volume":"207","author":"Ohoroh","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"10.1111\/jth.12224_bb0180","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1093\/humrep\/dei135","article-title":"ESHRE guideline for the diagnosis and treatment of endometriosis","volume":"20","author":"Kennedy","year":"2004","journal-title":"Hum Reprod"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.12224","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.12224","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622176889?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622176889?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jth.12224\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:03:10Z","timestamp":1761534190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622176889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S1538783622176889"],"URL":"https:\/\/doi.org\/10.1111\/jth.12224","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drospirenone and non-fatal venous thromboembolism: is there a risk difference by dosage of ethinyl-estradiol?","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.12224","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}